corporations
Switzerland: Pacrim takes control of Medropharm and prepares for a new phase of expansion in medicinal cannabis.
Pacrim has acquired two-thirds of Medropharm, a company in Switzerland, thus gaining control of the company and its business. The objective is to initiate a new phase of growth in the area of medicinal cannabis, with plans for international expansion and increased production capacity.
The Pacrim group has acquired a majority stake and full control of Medropharm AG, with the aim of consolidating a fully integrated medicinal cannabis supply chain and preparing the company for a new phase, according to a press release. The strategy behind the deal includes expanding current operations, establishing large-scale cultivation, and strengthening its presence in regulated markets such as Germany, the United Kingdom, and Australia.
The integration concentrates the entire production cycle in a single structure and will allow medicinal products to be placed directly in Swiss pharmacies. Pacrim and its subsidiary Alponics, a cultivation company associated with the cultivation of hemp flowers, will also increase their reach within the production chain, making it possible to establish a fully integrated model in the Swiss value chain.
According to Patrick Widmer, one of the founders of Medropharm, the deal confirms that the transaction, whose value remains confidential, responds to the need to "strengthen leadership, ensure financial stability and enable investments in infrastructure." Widmer also stated that this deal will allow the company to pursue projects that would be "too demanding to be supported solely by the company's cash flow." Medropharm's CEO, Claudia Zieres-Nauth, highlighted that Pacrim represents "a reliable partner with a long-term vision and a focus on quality."
With over 25 years of history through Pacific Rim Plantation Services, Pacrim reinforced its presence in the sector by creating, in 2018, the Swiss holding company Pacrim SA and its industrial unit Alponics SA, focused on hemp extracts and flowers with full traceability. The acquisition of Medropharm now marks the group's entry into the medicinal sector, supporting a vertically integrated production model with international ambitions.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
I am one of the directors of CannaReporter, which I founded together with Laura Ramos. I am from the unique Island of Madeira, where I currently reside. While I was in Lisbon at FCUL studying Physical Engineering, I became involved in the national hemp and cannabis scene and participated in several associations, some of which I am still a member of. I follow the global industry and especially legislative advances regarding the different uses of cannabis.
I can be contacted by email at joao.costa@cannareporter.eu



